Generation and analysis of new mouse models to determine novel therapeutic targets for Down syndrome-associated cognitive deficits
- Institution
- ROSWELL PARK CANCER INSTITUTE CORP, NY
- Principal investigator
- Eugene Yu
- Funding
- $116K
- Duration
- 2022–2027
Moonbase score
Still being scored
Abstract
In the United States, Down syndrome occurs in approximately one in every 691 newborns and presents with a constellation of clinical manifestations. It results from human trisomy 21, the most common chromosomal abnormality associated with intellectual disabilities. Currently, there are no effective treatments for the intellectual disabilities linked to Down syndrome, underscoring the urgent need for innovative strategies to develop therapeutic interventions. The mouse remains the premier model organism for studying Down syndrome due to the presence of highly conserved orthologous regions between human chromosome 21 and three mouse genomic segments located on chromosomes 10, 16, and 17. A prevailing hypothesis in Down syndrome research posits that its phenotypes may be causally linked to dosage increases of genes located on human chromosome 21. In line with this hypothesis, extensive efforts have focused on generating and analyzing mouse models that carry an extra copy of these orthologous regions—typically achieved by duplicating the corresponding segments in the mouse genome. These duplication models are often combined with mice carrying targeted deletions of smaller genomic intervals within the duplicated regions to help identify critical dosage-sensitive loci. Progress in this field has been greatly accelerated by advances in Cre/loxP-mediated chromosome engineering technology. To generate long-range chromosomal duplications and deletions in mice via Cre/loxP-mediated recombination, two independent gene targeting events must be performed in mouse embryonic stem cells, followed by Cre-mediated recombination. To support this process, several genetic cassettes are employed, including those encoding antibiotic resistance. In this supplement project, we aim to re-examine an underexplored area of knowledge related to chromosome engineering technology. The success of our efforts will have significant implications for Down syndrome research and broader applications in genetic modeling and analysis.
LOADING MOONBASE SCORE
Questions for ROSWELL PARK CANCER INSTITUTE CORP
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Roswell Park Cancer Institute CorpNot yet scored
Generation and analysis of new mouse models to determine novel therapeutic targets for Down syndrome-associated cognitive deficits
Eugene Yu · $450K · 2022–2027
- NIH · Roswell Park Cancer Institute Corp69
Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation
Brian C Betts · $712K · 2023–2028
- NIH · Roswell Park Cancer Institute Corp46
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies
Anna Bianchi-Smiraglia · $384K · 2020–2026